Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma HoldingsSTU:2B30 +1.49%74 WACC % is 6.96% as of Jul. 15, 2026, which is 27% below its 10-year median of 9.59. GuruFocus rates STU:2B30 with a GF Score™ of 74/100 and a GF Value™ of €4.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Xeris Biopharma Holdings ranks better than 51.47% on this metric.
As of today (2026-07-15), Xeris Biopharma Holdings's weighted average cost of capital is 6.96%%. Xeris Biopharma Holdings's ROIC % is 17.03% (calculated using TTM income statement data).
Xeris Biopharma Holdings generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
For a comprehensive WACC calculation, please access the WACC Calculator.
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Xeris Biopharma Holdings's weighted average cost of capital is 6.96%%. Xeris Biopharma Holdings's ROIC % is 17.03% (calculated using TTM income statement data).
Xeris Biopharma Holdings generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings WACC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's WACC % distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Xeris Biopharma Holdings's market capitalization (E) is €1253.731 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Xeris Biopharma Holdings's latest one-year quarterly average Book Value of Debt (D) is €227.0382 Mil.
a) weight of equity = E / (E + D) = 1253.731 / (1253.731 + 227.0382) = 0.8467
b) weight of debt = D / (E + D) = 227.0382 / (1253.731 + 227.0382) = 0.1533
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.545%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Xeris Biopharma Holdings's beta is 0.2853.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.545% + 0.2853 * 6% = 6.2568%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Xeris Biopharma Holdings's interest expense (positive number) was €24.635 Mil. Its total Book Value of Debt (D) is €227.0382 Mil.
Cost of Debt = 24.635 / 227.0382 = 10.8506%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / 10.252 = 0%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (STU:2B30) has a WACC % of 6.96% as of Jul. 15, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Xeris Biopharma Holdings and its competitors. This is 27% below median its historical median of 9.59. Over the past decade, Xeris Biopharma Holdings' WACC % has ranged from 7.65 to 13.28. According to the industry distribution chart, Xeris Biopharma Holdings ranks #496 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 48.5%.
Is Xeris Biopharma Holdings' WACC % too high?
Xeris Biopharma Holdings' current WACC % of 6.96% is 27% below median its 10-year median of 9.59. Over the past 10 years, this metric has ranged from a low of 7.65 to a high of 13.28. The Drug Manufacturers industry median WACC % is 8.99. Xeris Biopharma Holdings' value of 6.96% is 22.6% below this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #496 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' WACC % compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #496 out of 1022 companies for WACC %. This puts Xeris Biopharma Holdings in the upper half of its industry. The industry median WACC % is 8.99. Xeris Biopharma Holdings' value of 6.96% is 22.6% below this benchmark. Historically, Xeris Biopharma Holdings' own WACC % has ranged from 7.65 to 13.28 over the past decade. While the company's 10-year median is 9.59 vs. the industry median of 8.99, Xeris Biopharma Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.99, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current WACC % of 6.96% is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current WACC % is 6.96%, which is 27% below median its own 10-year median of 9.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (STU:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.55, compared to a current price of €7.23 — trading 58.9% above its estimated fair value. The current WACC % is 6.96%, which is 27% below median its 10-year median of 9.59 and 22.6% below the Drug Manufacturers industry median of 8.99. Xeris Biopharma Holdings' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Xeris Biopharma Holdings (STU:2B30), the current WACC % is 6.96% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (STU:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €7.23 is trading 58.9% above its estimated GF Value™ of €4.55.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for STU:2B30:
WACC %: 6.96% (27% below median its 10-year median of 9.59)
GF Value™: €4.55 vs. price of €7.23 (58.9% above fair value)
Industry Position: 22.6% below the Drug Manufacturers median (#496 of 1022)
No single metric tells the full story. See the STU:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score
Get the complete analysis for STU:2B30
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2B30 has been successfully added to your 
